NASDAQ · Biotechnology · USD
ALX Oncology Holdings Inc. (ALXO) Stock Analysis
ALX Oncology Holdings Inc. (ALXO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ALXO Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.25
- Previous Close
- $1.24
- Day's Range
- 1.15–1.30
- 52-Week Range
- 0.86–2.66
- Volume
- 934.51K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.48
Valuation
- Market Cap
- $159.02M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.13
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$101.70M
- Shares Outstanding
- 138.28M
- 1-Year Return
- −29.88%
Dividend and dates
- Earnings Date
- November 6, 2026estimated
- Avg Volume
- 1.16M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ALXO closed at $1.15, −29.88% over 1 year.
ALX Oncology Holdings Inc. (ALXO) has a market capitalization of $159.02M.
In fiscal 2025, ALXO reported revenue of $0.00.
ALXO Stock Return by Calendar Year
ALX Oncology Holdings Inc. (ALXO) return since Jul 2020: what $10,000 became
- 1 year
- $10,000 $7,012
- −29.88%
- 5 years
- $10,000 $214
- −97.86%
- Since Jul 2020
- $10,000 $383
- −96.17%
If you had invested $10,000 in ALX Oncology Holdings Inc. (ALXO) at the close on July 17, 2020, the earliest close on record here, it would have been worth $383 at the close on October 21, 2026: −96.17% in total, −40.60% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +1.77% |
| 2025 | −32.34% |
| 2024 | −88.78% |
| 2023 | +32.12% |
| 2022 | −47.56% |
| 2021 | −75.07% |
| 2020 (partial year) | +187.33% |
As of October 21, 2026.
ALXO Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$101.70M | — |
| 2024 | $0.00 | −$134.85M | — |
| 2023 | $0.00 | −$160.81M | — |
| 2022 | $0.00 | −$123.48M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$100.85M | −$101.70M | — |
| 2024 | $0.00 | — | −$142.47M | −$134.85M | — |
| 2023 | $0.00 | — | −$170.28M | −$160.81M | — |
| 2022 | $0.00 | $0.00 | −$127.44M | −$123.48M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
YahooALX Oncology Holdings Announces Publication Of Clinical Data From Its ASPEN-06 Randomized Phase 2 Clinical Trial In Nature Medicine, Showing Durable Clinical Benefit With Evorpacept In HER2-Positive Gastric Cancer
BenzingaALX Oncology to Present at Upcoming Investor Conferences in September
YahooALX Oncology Holdings Q2 Adj. EPS $(0.11) Beats $(0.14) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B